Research Progress on Advanced Renal Cell Carcinoma

Overview

Journal J Int Med Res

Publisher Sage Publications

Specialty General Medicine

Date 2020 Jun 13

PMID 32529862

Citations 6

Authors

Xin-da Song

Yi-Nong Tian

Hao Li

Bin Liu

Ai-Li Zhang

Yang Hong

Affiliations

Soon will be listed here.

Abstract

Renal cell carcinoma (RCC) is a malignant tumor and the third most common urinary disease. It was estimated that RCC affected over 350,000 individuals in 2013, and there are nearly 140,000 deaths annually due to this disease. The initial masses in RCC patients are mostly confined to a single organ. However, due to the metastatic spread of cancer cells through the circulatory system, more than 30% of RCC patients relapse after surgery. The appearance of distant metastases often means that patients enter the advanced stage of cancer with low quality of life and a short expected survival time. This review aims to describe the extant research on advanced RCC, including its pathophysiology, heterogeneity, diagnosis, treatment, and prospects. We try to highlight the most suitable means of treating advanced RCC patients, focusing on comprehensive personalized treatments.

Citing Articles

Comparing Sonazoid contrast-enhanced ultrasound to contrast-enhanced CT and MRI for differentially diagnosing renal lesions: a prospective multicenter study.

Zhao Q, Wu C, Tan S, Yang Y, Cui X, Dietrich C World J Urol. 2024; 42(1):302.

PMID: 38720010 DOI: 10.1007/s00345-024-04885-7.

Bioinformatic Analysis and Clinical Case Studies Identify CD276 as a Promising Diagnostic Biomarker for Clear Cell Renal Cell Carcinoma.

Zhang Z, Xu J, Song Z, Zhang J, Lin Y, Ouyang J Cancer Control. 2024; 31:10732748241250181.

PMID: 38669187 PMC: 11055485. DOI: 10.1177/10732748241250181.

ExPert ConsEnsus on the management of Advanced clear-cell RenaL celL carcinoma: INDIAn Perspective (PEARL-INDIA).

Sahoo T, Desai C, Agarwal S, Rauthan A, Dhabhar B, Biswas G BMC Cancer. 2023; 23(1):737.

PMID: 37558975 PMC: 10413514. DOI: 10.1186/s12885-023-11237-y.

Speckle-type POZ protein could play a potential inhibitory role in human renal cell carcinoma.

Chen Z, Li Z, Li C, Li B, Wang H, Nong D BMC Cancer. 2022; 22(1):1277.

PMID: 36474188 PMC: 9727862. DOI: 10.1186/s12885-022-10340-w.

A Randomized Study on the Effect of Metformin Combined with Intensive-Exercise Diet Therapy on Glucose and Lipid Metabolism and Islet Function in Patients with Renal Cell Carcinoma and Diabetes.

Liu Y, Meng L, Li J, Jin Y, An R Dis Markers. 2022; 2022:7383745.

PMID: 35872697 PMC: 9307380. DOI: 10.1155/2022/7383745.

References

Flanigan R, Campbell S, Clark J, Picken M . Metastatic renal cell carcinoma. Curr Treat Options Oncol. 2003; 4(5):385-90. DOI: 10.1007/s11864-003-0039-2. View

Motzer R, Escudier B, Tomczak P, Hutson T, Michaelson M, Negrier S . Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013; 14(6):552-62. DOI: 10.1016/S1470-2045(13)70093-7. View

Ibragimova I, Maradeo M, Dulaimi E, Cairns P . Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC. Epigenetics. 2013; 8(5):486-93. PMC: 3741218. DOI: 10.4161/epi.24552. View

Burrell R, McGranahan N, Bartek J, Swanton C . The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013; 501(7467):338-45. DOI: 10.1038/nature12625. View

Zhang B, Wu Q, Wang Z, Xu R, Hu X, Sun Y . The promising novel biomarkers and candidate small molecule drugs in kidney renal clear cell carcinoma: Evidence from bioinformatics analysis of high-throughput data. Mol Genet Genomic Med. 2019; 7(5):e607. PMC: 6503072. DOI: 10.1002/mgg3.607. View

Ikuerowo S, Ojewuyi O, Omisanjo O, Abolarinwa A, Bioku M, Doherty A . Paraneoplastic syndromes and oncological outcomes in renal cancer. Niger J Clin Pract. 2019; 22(9):1271-1275. DOI: 10.4103/njcp.njcp_35_19. View

Bukowski R . Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma. Front Oncol. 2012; 2:13. PMC: 3356077. DOI: 10.3389/fonc.2012.00013. View

Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M . EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015; 67(5):913-24. DOI: 10.1016/j.eururo.2015.01.005. View

Vasudev N, Larkin J . Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib. Clin Med Insights Oncol. 2011; 5:333-42. PMC: 3210627. DOI: 10.4137/CMO.S7263. View

10.

Sun M, Larcher A, Karakiewicz P . Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence. Int J Nephrol Renovasc Dis. 2014; 7:401-7. PMC: 4219683. DOI: 10.2147/IJNRD.S48496. View

11.

Heng D, Wells J, Rini B, Beuselinck B, Lee J, Knox J . Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2014; 66(4):704-10. DOI: 10.1016/j.eururo.2014.05.034. View

12.

Vora A, Brodsky R, Nolan J, Ram S, Richter L, Yingling C . Incidence of postembolization syndrome after complete renal angioinfarction: a single-institution experience over four years. Scand J Urol. 2013; 48(3):245-51. DOI: 10.3109/21681805.2013.852620. View

13.

Sternberg C, Davis I, Mardiak J, Szczylik C, Lee E, Wagstaff J . Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28(6):1061-8. DOI: 10.1200/JCO.2009.23.9764. View

14.

Adibi M, Thomas A, Borregales L, Matin S, Wood C, Karam J . Surgical considerations for patients with metastatic renal cell carcinoma. Urol Oncol. 2015; 33(12):528-37. DOI: 10.1016/j.urolonc.2015.10.003. View

15.

Muniz D, Ratto B, Yang H, Zhao J, Jenkins M, Signorovitch J . Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America. Adv Ther. 2019; 36(12):3446-3457. DOI: 10.1007/s12325-019-01109-y. View

16.

Carlo M, Voss M, Motzer R . Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. Nat Rev Urol. 2016; 13(7):420-31. PMC: 5532875. DOI: 10.1038/nrurol.2016.103. View

17.

Ball M, Bezerra S, Gorin M, Cowan M, Pavlovich C, Pierorazio P . Grade heterogeneity in small renal masses: potential implications for renal mass biopsy. J Urol. 2014; 193(1):36-40. DOI: 10.1016/j.juro.2014.06.067. View

18.

Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S . Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010; 28(13):2144-50. DOI: 10.1200/JCO.2009.26.7849. View

19.

Gu L, Ma X, Li H, Chen L, Xie Y, Li X . Comparison of oncologic outcomes between partial and radical nephrectomy for localized renal cell carcinoma: A systematic review and meta-analysis. Surg Oncol. 2016; 25(4):385-393. DOI: 10.1016/j.suronc.2016.09.001. View

20.

Mutlu H, Gunduz S, Buyukcelik A, Yildiz O, Uysal M, Tural D . The necessity of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma using antiangiogenic targeted therapy after interferon alfa-2b. Clin Genitourin Cancer. 2014; 12(6):447-50. DOI: 10.1016/j.clgc.2014.06.006. View